BioCryst Pharmaceuticals, Inc. reports financial results for the fourth quarter and full year ended 31 December 2022, and provides a corporate update.

“It has been exciting to build on our strong initial launch by doubling ORLADEYO revenues in our second year, and to see the expanding global reach of an oral, once-daily therapy that is changing the lives of patients with HAE and their families,” says Jon Stonehouse, President and CEO of BioCryst.

Program Updates and Key Milestones (excerpts)

  • New patient demand for ORLADEYO was strong in the fourth quarter, consistent with the steady growth trajectory observed since launch.
  • The ORLADEYO prescriber base continues to grow significantly, with approximately half of the new prescriptions in the fourth quarter coming from the top 500 prescribers.
  • The total number of patients on ORLADEYO at year-end 2022 was consistent with the company’s expectations.
  • The company expects patient growth in Q1 2023 to remain strong.
  • The Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee has recently issued a final draft positive recommendation for ORLADEYO to be reimbursed for the routine prevention of HAE attacks in adults and pediatric patients 12 years of age and older.

“Underlying demand from patients and physicians for ORLADEYO continues to be strong and consistent in the U.S., and our initial European launches are gaining traction with ORLADEYO now commercially available in 15 countries. All of this enables more and more patients to benefit from ORLADEYO”, says Charlie Gayer, Chief Commercial Officer of BioCryst.
(Source: BioCryst)